Booken N, Schumann T, Fuchslocher M, Goerdt S, Goebeler M
Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Mannheim, Medizinische Fakultät Mannheim der Universität Heidelberg, Theodor-Kutzer-Ufer 1-3, 68135, Mannheim.
Hautarzt. 2010 Mar;61(3):246-9. doi: 10.1007/s00105-009-1767-4.
The therapy of discoid lupus erythematosus (DLE) is occasionally a therapeutic challenge. Topical treatment is often not sufficient and therapy with antimalarials [(hydroxy-) chloroquine] not always successful. We report on a 50-year-old male patient with recalcitrant chronic DLE who experienced within 12 weeks at first improvement and then almost complete remission for 11 months after off-label application of the anti-CD11a antibody efalizumab.
盘状红斑狼疮（DLE）的治疗有时是一项治疗挑战。局部治疗往往不够充分，使用抗疟药（如羟氯喹）进行治疗也并非总能成功。我们报告了一名50岁的男性患者，患有顽固性慢性DLE，在超适应症使用抗CD11a抗体依法利珠单抗后，12周内病情首先有所改善，随后几乎完全缓解达11个月。
